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Summary
The B7-1 molecule, expressed on antigen presenting cells(APC), provides a crucial costimulatory
signal for T cell activation. Recent studies demonstrate the existence of alternative, non-B7-1
CTLA4 counter-receptors in mice and humans. Here, we describe the molecular cloning and
demonstrate costimulatory function of the murine B7-2 (mB7-2) gene. Murine B7-2 cDNA
encodes a member of the Ig supergene family that binds CTLA4-Ig and stains with the GL1
but not anti-mB7-1 mAb. Murine B7-2 costimulates the proliferation and interleukin 2 production
of CD4+ T cells and this costimulation can be inhibited by either CTLA4-Ig or GL1 mAb.
Identification of the B7-2 molecule will permit further manipulation of the B7:CD28/CTLA4
costimulatory pathway which has been shown to be involved in the prevention of tolerance,
induction of tumor immunity, and most recently, in the pathogenesis of autoimmunity.
T
o induce antigen-specific T cell clonal expansion, two
signals provided by APC must be delivered to resting
T lymphocytes (1, 2). The first signal, which confers specificity,
is mediated via the TCR after recognition of an antigenic
peptide presented by the MHC. The second signal, termed
costimulation, induces T cells to proliferate. Costimulation
is neither antigen specific, nor MHC restricted, and is deliv-
ered by cell surface molecules expressed by APCs (3, 4). Orig-
inally termed B7 in mice and humans, B7-1 is one such crit-
ical costimulatory molecule (5-7) . B7-1 is the counter-receptor
for two ligands expressed on T lymphocytes (8, 9). The first
ligand, termed CD28, is constitutively expressed on T cells,
and after ligation, induces IL-2 secretion and proliferation
(10). The second ligand, termed CTLA4, is homologous to
CD28 and appears on T cells after activation (11). Although
CTLA4 has a significantly higher affinity for B7 than does
CD28, its rolein T cell activationremains to be determined(9).
We and others have considerable evidence for the existence
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of multiple non-B7-1, CTLA4 counter-receptors which
costimulate T cell proliferation and IL-2 production. APCs
from B7-1-deficient mice bind CTLA4-Ig (12) and costimu-
late T cell proliferation which is inhibited by CTLA4-1g.
Activated murine B lymphocytes express functional non-
mB7-1, CTLA4 counter-receptor(s) which appears signi-
ficantly earlier after activation than murine B7-1 (mB7-1)1
(13). The GL1 mAb identifies one such non-B7-1, CTLA4
counter-receptor (14). Similarly, activated human B cells ex-
pressmultiple CTLA4 counter-receptors distinguished by their
selective reactivity with mAbs and their temporal expression
(15).
Here, we report the cloning and functional analysis of the
murine B7-2 cDNA (mB7-2). Murine B7-2 binds CTLA4-
Ig, costimulates T cell proliferation and IL-2 production, and
is defined by the GL1 mAb.
1 Abbreviation used in this paper. mB7-2, murine B7-2.
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Isolation ofmB7-2cDNA.
￿
AcDNA librarywas prepared in the
pCDM8 expression vector using poly(A)' RNAfrom cyclic AMP
(300 /~g/ml)-stimulated M12 murine B cell line (RNA harvested
at 0, 8, 19, 27, 32,and48 h) (16). COS cellswere transfected with
the activated M12 cDNA library DNA by DEAE-dextran trans-
fection (17). Cells were harvested after 47 b, incubated with 10
P,g/ml bCTLA4-Ig and mCD28-Ig, and binding cells were iso-
lated by panning on goat anti-human IgG coated plates (18).
Episomal DNA was isolated, transformed into Escherichia coli
DH10B/P3, and the plasmid DNA reintroduced into COS cells
via spheroplast fusion. Transfected cells were harvested after47 h.
Cells expressing B7-1 were removed by incubation with anti-mB7-1
mAb (16-10A1) and immunomagnetic bead depletion using anti-
mouse IgM and IgG coated beads. Transfectants were selected by
panningwith hCTLA4-Igand mCD28-Ig as describedabove, and
plasmid DNA wastransformed into E. coli. A thirdroundof selec-
tion, identical to the second round was performed, after which
plasmidDNA was isolated from individual transformants. Six of
seven isolatedplasmids contained a 1.2-kbcDNA insert . COScells
transfected with theseplasmids bound CTLA4-Ig but not control
Ig fusion protein.
DNA Sequence Analysis.
￿
Murine B7-2 cDNA insert (clone 4)
was subcloned into the pKSII- plasmid. The cDNA insert was se-
quenced on both strands using synthetic oligonucleotide primers
anddye-labeled terminator/Taq polymerase chemistry, and analyzed
on an automatedfluorescent DNAsequencer(Applied Biosystems,
Foster City, CA). Thesesequence data are available from EMBL/
GenBank/DDBJ under accession number L25606.
B7 Hybridization Probes andRNA Blot Hybridization.
￿
The en-
tire mB7-2 cDNA was used as a probe for RNA hybridizations.
RNA wasprepared from the unstimulated andc-AMP-stimulated
M12Bcell line (16) andfrom theBcell lymphomas, A20 and TA3,
the NS-1 plasmacytoma, and 70 Z pre-B cell lines. RNA prepara-
tion,detailed characterizations, and sources ofthesecellsareas de-
scribed (19). RNAwas denaturedwith formaldehyde, electropho-
resed on an agarose gel, andblotted onto nitrocellulose membranes
(Schleicher & Schuell, Inc., Keene, NH). The mB7-2 and actin
cDNA insert (control for RNA amount and integrity) were la-
beled by random oligonucleotide priming using tx31P-labeled
dCTP anddATP and the Klenow Fragment of DNA polymerase.
Hybridization, washing, and autoradiography were performed as
described previously (11).
COS Cell Transfection.
￿
Transient expression of cDNA clones
in COS cells was performed as described previously (17). COS cells
were transfected with cDNAs encoding mB7-1 (5), B7-2 or hB7-2,
or with pCDNAI vector alone. Transfected COS cells were used
72 h after the addition of DNA.
Fluorescence Activated Cell Sorting.
￿
Purified murine Bcells were
stimulated in vitro with LPS (10 Ecg/ml) and dextran sulfate (20
Ag/ml) (6), andstained with anti-B7 (16-10A1)(6), GLImAb (14),
hCTLA4-Ig (2), or isotype-matched controls, followed by goat
anti-hamster Ig FITC, goat anti-rat Ig FITC, or donkey
anti-human Ig FITC, respectively.The GL1 mAbidentifies a65-100
kD glycoprotein expressed at low levels on resting murine B cells
and expression increases with activation. GLI mAb blocks the
bindingofCTLA4-Ig on LPS-activated Bblasts and, in vivo, func-
tionally blocks the induction of IgM Ab formation to BSA-FITC.
Cells were then washed, fixed in 1% paraformaldehyde in PBS,
and analyzed by flow cytometric analysis.
Proliferation Assay.
￿
Mouse Tcells were purified as describedpre-
viously (20). Briefly, spleen cells were depleted oferythrocytes by
treatmentwith Tris/NH4C1. T cells were enriched by nylon wool
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fractionation. CD4' T cells from BALB/c mice were purified by
treatmentwith amixtureofanti-MHC classII andanti-CD8 mAbs
and rabbit complement (Cedarlane Laboratories, Hornby, ON,
Canada). Murine T cells were stimulated with either soluble anti-
CD3 (1:100-1:3,000 dilution oftissue culture supernatant) or PMA
(Calbiochem-Novabiochem Corp., La Jolla, CA) at 1-20 ng/ml.
Human CD28' T lymphocytes were purified as described previ-
ously (21) and stimulated with PMA at 1 ng/ml final concentra-
tion. COS cell transfectants were incubated with 25 t~g/ml of
mitomycinC for3 h, washed extensively, andthen added at acon-
centration of 2 x 104 cells/well. The specificity of the stimula-
tion with COS-transfectedcellswasassayed by theaddition of anti-
m137-1 mAb (16-10M) (6), GL1 mAb (14), or CTLA4-Ig (2), and
appropriate isotype-matched control Abs. The cells were pulsed
with 1 ACi of [3H]thymidine (ICN Flow, Costa Mesa, CA) dur-
ing thelast 16 h ofa60-h culture, harvestedonto filters, andcounted.
Microcultures were setup in triplicate in 96-well plates as described.
T cells, (10s/well), were cocultured with transfectants in 0.2 ml
of RPMI supplemented with 10% FCS, 4 MM L-glutamine, 10
mM Hepes, and antibiotics.
11,2 Assay.
￿
ILr2 accumulation was assayed using an 11,2 ELISA
kit (Endogen, Inc., Boston, MA) according to the manufacturer's
instructions. Supernatants foranalysis were removedfrom microcul-
ture wells after 24 h of culture. Supernatants from triplicate cul-
tures were pooled and assayed in duplicate by ELISA.
Results
Murine B7-2 cDNA, Isolation and Expression.
￿
A 1.2-kb
cDNA encoding a CTLA4 binding protein was isolated by
cDNA expression cloningfrom acDNA library prepared from
cyclic AMP-activated M12 murine B lymphoma cells. When
transfected into COS cells, this cDNA directed the synthesis
of a molecule whichbound CTLA4-Ig (Fig. 1). Furthermore,
the mB7-2 COS transfectants stained with the GL1 mAb
whichidentifies anon-mB7-1, CTLA-4 counter-receptor ex-
pressed on activated murine B cells. This mAb is a potent
inhibitor of costimulation delivered by murine APCs (14).
A very slight shift in fluorescence intensity wasobserved when
anti-mB7-1 mAb was used to stain mB7-2 transfected COS
cells. In contrast, mB7-1 COS transfectants bound CTLA4-
Ig and stained with anti-mB7 but not GL1 mAb. None of
these transfected COS cells bound control Ig fusion protein
or isotype-matched controlmAbs. Similarly, COS cellstrans-
fected with vector alone did not bind any of the aforemen-
tioned reagents (Fig. 1 and data not shown).
ThemB7-2 cDNA is comprisedof 1,183 nucleotides, and
exhibits asingle large open reading frameof 927nucleotides.
The encoded polypeptide is 309 amino acids long and ex-
hibits many features common to type I Ig superfamily mem-
brane proteins (Fig. 2 A). The NHZ terminus of the B7-2
protein (amino acids 1-23) has the characteristics of a secre-
tory signal peptide with apredictedcleavage after thealanine
at position 23. The mature protein would consist of an ap-
proximately 222 amino acid extracellular region containing
Ig superfamily V and C-like domains, a hydrophobic trans-
membrane domain ofabout20 amino acids, and acytoplasmic
tail of approximately 44 amino acids. The mB7-2 protein is
predicted to have a molecular weight of 32,195 before
modification. The B7-2 extracellular domain contains ninemB7-2
mB7-1
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Figure 1.
￿
mB7-2 binds CTLA4-Ig and GL1 mAb but not anti-mB7-1
mAb. COS cells were transfectedwith pCDNA1 alone (vector) or expres-
sion plasmid encoding cDNAs for mB7-2 or mB7-1. Transfectants were
stained with,recombinant CTLA4-1g, anti-mB7-1 mAb (16-10A1), GL1
mAb or appropriate isotype-matched controls, Ab binding was detected
by indirect immunofluorescence and flow cytometric analysis. Staining of
mB7-2 transfected COS cells (top), mB7-1 transfected cells (middle), and
vector alone (bottom). (Thin lines) Staining with isotype-matched control
Abs or control Ig fusion protein; (thick lines) staining with CTLA4-1g,
anti-B7-1 mAb, or GM mAb. This data is representativeoffour experiments.
potential Winked glycosylation sites. The glycoprotein im-
munoprecipitated by the GM mAb has a molecular weight
of 60-100 kd, which reduces to 34 kD afterN-glycanase treat-
ment (14), suggesting that the mB7-2 protein is heavily
glycosylated. Comparisonofboth nucleotide and amino acid
sequences ofmB7-2 with the GenBank and EMBL databases
and with our recently identified human B7-2 has shown that
only the human B7-2 protein is closely related, with 50%
amino acid identity, and that murine and human B7-1 are
distantly related. The alignment of murine and human B7-1
and B7-2 protein sequences shows that the homology is con-
centrated in the Ig-like domains with the transmembrane,
and cytoplasmic domains being much less conserved (Fig. 2
B) . Comparison of the four characterized B7 proteins (Fig.
2 B) reveals that the IgV- and Ig-C-like domains demon-
strate 14 and 18% amino acid identity, respectively. In general,
conserved amino acids other than those involved in the ca-
nonical Ig structure tend to be concentrated in the sequences
at the bottom of the IgV and the top of the IgC domains.
In particular, the sequence SQD(P/N)(E/V)(S/T)EL(Y/F),
predicted to be the loop between the D and E (3 strands of
the IgC domain, is conserved (22). Whether this sequence
is required for the structural integrity of B7-like molecules
or represents a required motif for CTLA4 binding is not yet
clear. But since human B7-1, human B7-2,murine B7-1, and
murine B7-2 all bind to human CTLA4, the homologous
amino acids probably represent those necessary to comprise
a CTLA4 binding sequence.
Expression ofmB7-2 mRNA.
￿
Two mRNA transcripts of
1.8 and 3.1 kb were identifiedby hybridization to the mB7-2
cDNA (Fig. 3). RNA blot analysis of c-AMP-treated M12
cells demonstrates that B7-2 is not expressed in unstimulated
M12 cells, but is induced by c-AMP treatment by 8 h and
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Comparison ofmurine and human B7-1 and B7-2 amino acid
sequences. (A) All amino acid identities between mB7-2 and hB7-2 are
indicated with a vertical bar. Only those amino acids present in hB7-1
and mB7-1 which are common to murine and human B7-1 are marked.
Amino acids at B7-1 exon boundaries are bolded and underlined. (B) Per-
centage of identity for each B7 domain was calculated using as domains
the exon boundaries determined for mB7-1 and hB7-1.Figure 3 .
￿
mB7-2mRNA expression in unstimulated and cAMRstimulated M12 cells and in B cell lines . 20 jug oftotal RNA (A) or 5 pg ofpoly(A)4
RNA (B) were electrophoresed on agarose gels and transferred to nitrocellulose membranes . The blots were hybridized with 32P-labeled mB7-2cDNA.
The lanes contain RNA prepared from (A) unstimulated M12 B cells or activated withcAMP as described in Materials and Methods for the indicated
times or (B) the 70Z pre-B cell line, the NS-1 plasmacytoma line, and the A20 and TA3 B cell lymphoma cell lines. The mobility ofrRNAs is indicated .
declines only slightly by 27-48 h . In contrast, mB7-1 expres-
sion induced by c-AMP is highest after 27 h (23) . mB7-2
mRNA expression was detected in the TA3B cell line, a fre-
quently used murine APC line. Very low levels of mB7-2
mRNA were seen in the A20 B cell line but are sufficient
for moderate levels ofmB7-2 cell surface expression asshown
by GL1 staining of A20 cells (data not shown) . However,
mB7-2mRNA was not detected in the NS-1 plasmacytoma
or the pre-B cell line 70Z. In contrast, B7-1 mRNA is ex-
pressed in NS-1 and A20 cells but not 70Z or TA3 (5) .
Induction of mB7-2 on LPS/Dextran Stimulated Murine B
Cells . MurineB cells from wild-type and B7-1-deficient mice
were isolated and activated with LPS/dextran for 72 h . As
seen in Fig. 4, upon stimulation both B7-1 wild-type and
deficient B cells bind CTLA4-1g. When GL1 mAb was used
to stain B7-1 wild-type and B7-1-deficient B cells, a similar
pattern of staining was observed . However, low levels ofGL1
staining were seen on unstimulated B cells. In contrast, anti-
mB7-1mAb stained LPS/dextran-stimulated wild-typeB cells
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Figure 4.
￿
Expression ofmB7-1 and mB7-2 in unstimulated and stimu-
lated murine B cells. Highly purified B cells were prepared from wild-type
and B7-1-deficient mice (12). Both populations were used for expression
studies either without stimulation or at 72 h after stimulation with LPS/dex-
tran . (Thin line) Isotype-matched control Abs ; (thick line) anti-mB7-1 mAb,
GLI mAb, or CTLA4-Ig staining . Ab binding was detected by indirect
immunofluorescence and flow cytometricanalysis . This data is representa-
tive of three experiments.but not B cells isolated from mB7-1-deficient mice. These
results are consistent with those recently observed by Freeman
et al. (12) .
Costimulatory Activity of mB7-2 .
￿
To determine whether
mB7-2 can costimulate submitogenically activated murineT
cells, CD4+ murine T cells were isolated and activated with
either PMA or soluble anti-CD3mAb (145-2C11) . Asshown
in Fig. 5 A, PMA-activatedT cells were costimulated by both
mB7-1 andmB7-2 but not vector-transfected COS cells . Simi-
larly, anti-CD3-activated T cells demonstrated significant
proliferation when cocultured with either mB7-1 or mB7-2
COS transfectants but not vector transfectants . (Fig. 5 B) .
Both proliferation and IL-2 accumulation induced by mB7-2
costimulation were inhibited by CTLA4-Ig and by theGM
mAb (Fig. 6) . This result is consistent with the recently
demonstrated inhibitory effect ofGM on costimulatory re-
sponses induced by heterologous APCs (14) . While mB7-1
mAb stained mB7-2 cDNA transfected COS cells only very
weakly, mB7-1 mAb consistently inhibited proliferation and
IL-2 accumulation induced by mB7-2 by ti 30-50% (five
experiments), suggesting the existence of a weakly cross-
reactive epitope . In contrast, mB7-1 costimulatory activity
was blocked CTLA4-Ig and by the anti-mB7-1 mAb but not
by GM mAb.
Both human B7-1 and murine B7-1 transfected COS cells
have been previously shown to provide costimulation to both
human and murine T cells (5) . We, therefore, also examined
the capacity ofhuman and murine B7-2 transfectedCOS to
Figure 5 .
￿
mB7-1 and mB7-2COS cell transfectants costimulate T cell
proliferation . The costimulatory capacity ofCOS cells expressing mB7-1
or mB7-2 was determined by mixing transfected COS cells with 105
BALB/c T lymphocytes stimulated with submitogenic levels ofPMA (A)
or anti-CD3 (B) . All T cell populations were depleted of detectable acces-
sory cells, as demonstrated by a lack of an anti-CD3 or PMA response
in the absence of a source of costimulatory activity . Wells contained 2
x 10 4 mitomycin C-treated COS cells transfected with vector alone,
mB7-1 or mB7-2. Cultures were pulsed after 48 h with 1 p,Ci of
[3H]thymidine per well for the last 16 h of the incubation period to assay
T cell proliferation. This data is representative of two experiments .
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Figure 6 .
￿
Inhibition of mB7-1 and mB7-2 costimulation. Microcul-
tures were set up as described with 105 BALB/c T lymphocytes . All T
cell populations were depleted of detectable accessory cells, as demonstrated
by a lack of an anti-CD3 (1 Ag/ml) or PMA (5 ng/ml) response in the
absence of a source of costimulatory activity. Wells contained 2 x 104
mitomycin C-treated COS cells transfected with vector alone, mB7-1, or
mB7-2 . Ab reagents were added at a final concentration of. CTLA4-Ig
and control Ig fusion protein, 2 ug/ml ; GLl mAb and rat control mAb,
0 .1 14g/ml ; and anti-B7-1 mAb and hamster control mAb, 1 1&g/ml. Su-
pernatants were harvested at 24 h for IL2 ELISA assay . Cultures were
pulsed after 48 h with 1 ACi of [ 3H]thymidine per well for the last 16 h
ofthe incubation period to assay T cell proliferation. This data is represen-
tative of three experiments .
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Figure 7 .
￿
Human andmurine B7-2costimulate T cell proliferation across
species . Human CD28+ T lymphocytes (A) and murineCD4+ T cells
(B) were treated with PMA (5 ng/ml) and mixed with 2 x 10 4
mitomycin C-treatedCOS cells expressing hB7-2, mB7-1, mB7-2, or trans-
fected with vector alone. All T cell populations were depleted of detect-
able accessory cells, as demonstrated by a lack of an anti-CD3 or PMA
responsein the absenceofa source ofcostimulatory activity. Cultureswere
pulsed after 48 h with 1 p.Ci of f3H]thymidine per well for the last 16 h
ofthe incubationperiod to assay T cell proliferation . This data isrepresen-
tative of two experiments.costimulate across species. Fig. 7 B demonstrates that sub-
mitogenically activated murine T cellsproliferate in response
to hB7-2 COS transfectants, as well as to mB7-1 and mB7-2
COS transfects. Similarly, human PMA-activated T cells
proliferate in response to mB7-2, as well as to hB7-2. (Fig.
7 A) .
Discussion
In this report, we describe the molecular cloning, expres-
sion, and costimulatory function ofthe mB7-2 gene. Although
demonstrating only 25% amino acid identity with mB7-1,
mB7-2cDNA encodes a member of the Ig supergene family
that binds CLTA4-Ig and costimulates T cells to produce IL-2
and proliferate. In contrast to mB7-1, mB7-2 transfected COS
cells stain with the GLI mAb but do not stain with mB7-1
mAb. Costimulation induced by mB7-2 transfectants is in-
hibited by CTLA4-Ig and GL1 mAb. These results demon-
strate that the mB7-2 cDNA encodes a second CTLA4
counter-receptor that is identifiedby the GL1 mAb and which
costimulates T cell proliferation and IL-2 production.
The cloning of mB7-2 and its reactivity with the GL1 mAb
confirms the existence of a novel murine CTLA4 counter-
receptor expressed within hours after B cell activation. These
data are consistent with recent experiments suggesting the
existence of additional ligands for CTLA4, distinct from
mB7-1, on activated splenic B cells (12, 13, 24). In this manu-
script, we show that LPS/dextran-activated murine B cells
derived from the mB7-1-deficient mouse strain bind CTLA4-
Ig and stain with the GL1 but not with anti-mB7-1 mAb.
Recently, Lenschow et al. (13) demonstrated that by 6 h after
activation, murine B cellsexpress a CTLA4 counter-receptor
distinct from mB7-1. This molecule appears on the cell sur-
face -24 h earlier than mB7-1 and unlike mB7-1, its expres-
sion is induced by Con A. GL1 is expressed at low levels on
unstimulated murine B cells and rapidly increases with acti-
vation. The GL1 mAb abrogates costimulation induced by
populations containing activated murine B cells (14). Cyclic
AMP induces mB7-2 mRNA more rapidly than mB7-1
mRNA, suggesting that mB7-2, like mB7-1, is upregulated
by cross-linking ofMHC classII (23) but is expressed sooner
than mB7-1. Taken together, these results suggest that the
mB7-2 molecule appears earlier than mB7-1 and is respon-
sible, at least in part, for the costimulation delivered by APCs
within the first 24 h.
Many experiments examining the costimulatory capacity
of natural APCs use chemically fixed APCs (1, 30). We have
found that costimulatorys have very different sensitivities to
fixation. The costimulatory capacity ofB7-2 is partially sen-
sitive to paraformaldehyde fixation, whereas B7-1 costimula-
tion is insensitive to paraformaldehyde fixation (5, Freeman,
G., unpublished results). ICAM-1 costimulation (27) is elim-
inated by paraformaldehyde fixation. Thus the costimulatory
capacity ofnative APCs may be different than those ofchem-
ically fixed APCs and should be considered when interpreting
experiments using fixed APCs.
Virtually identical evidence exists for an early, non-B7-1,
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CTLA4 counter-receptor in humans (hB7-2) (15, 25) . Be-
tween 12 and 24 h after activation, human B cells express
a non-hB7-1, CTLA4 counter-receptor which costimulates
CD28+ T cells to proliferate and secrete IL-2. This costimu-
lation is abrogated by blocking with CTLA4-Ig and anti-
CD28 Fab but not by anti-hB7-1 mAb (133) (15) . Recently,
we have molecularly cloned the human B7-2 cDNA (25) .
The hB7-2 cDNA demonstrates 26% amino acid identity
with hB7-1 and 50% identity with mB7-2. Like hB7-1, hB7-2
costimulates T cell proliferation and IL-2 secretion and this
costimulation is inhibited by both CTLA4-Ig and anti-CD28
Fab (25) . Whereas hB7-1 mRNA is not detected in unstimu-
lated B cells, hB7-2 mRNA is constitutively expressed in un-
stimulated B cells and increases after activation. Since no
CTLA4 counter-receptors are expressed on the surface of un-
stimulated B cells (15), the constitutive expression of hB7-2
mRNA suggests a posttranscriptional regulation of hB7-2
expression.
Although mAbs directed against hB72 are currently un-
available, the constitutive expression of hB7-2 mRNA and
the observed costimulatory capacity of 24-h activated human
B cells suggests that hB7-2 also appears early afterB cell acti-
vation. Whereas the signaling function of CTLA4 in mu-
rine and human systems has yet to be resolved, hB7-1 and
hB7-2 appear to signal via CD28 (15, 25). Although we do
not yet have an antimurine CD28 Fab to address this issue
directly, we postulate that mB7-2 also signals via CD28. In-
direct evidence for this hypothesis is derived from the obser-
vation that mB7-2 and hB7-2, like mB7-1 and hB7-1, costimu-
late T cell proliferation and IL-2 production across species
barriers. These results demonstrate the striking evolutionary
conservation displayed by murineand human B7-1 and B7-2
for their receptors CD28 and CTLA4 expressed on T lym-
phocytes.
These results indicate that the B7:CD28/CTLA4 pathway
has additional levels of complexity. The biologic function(s)
for multiple, sequentially induced CTLA4 counter-receptors
remains to be elucidated. Howevef, the early appearance of
B7-2 provides one mechanism for B cell-induced costimula-
tion at a time before the induction of B7-1. Therefore, the
early expression of B7-2 suggests that it may provide a crit-
ical costimulatory signal involved in the decision between
immunity and anergy that is made by T cells within 24 h
after activation (2, 26, 27). Furthermore, it may be that B7-1
serves to amplify rather than initiate an immune response.
Recent data in the human system demonstrating a third
CTLA4 counter-receptor suggest that the B7:CD28/CTLA4
pathway is even more complex. Specifically, B7-1-negative,
activated human B cells express a BB1 molecule which is dis-
tinct from hB7-1 and hB7-2 (15). It may be that subpopula-
tions of APCs differentially express these CTLA4 counter-
receptors. It is presently unknown whether additional T cell
receptors for the B7 family ofcostimulatory molecules exist.
The capacity of the CD28-deficient mouse to generate an
immune response and produce low levels of IL-2 is consis-
tent with this hypothesis (28). Since this pathway appears
to be central to the initiation and amplification of a T cell-mediated immune response, it is not surprising that it is highly
regulated. Elucidating these levels of regulation should en-
able us to manipulate this critical costimulatory pathwaywhich
already has been shown to be involved in the regulation of
tolerance (2, 29, 30), induction of tumorimmunity (31, 32,
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